Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:20 AM
Ignite Modification Date:
2025-12-25 @ 3:20 AM
NCT ID:
NCT03128905
Eligibility Criteria:
Inclusion Criteria:
* Patient aged 65 and older
* Patient with mono/polyarticular CPPD acute arthritis
* Hospitalized patient (without infectious syndrome considered insufficiently controlled by the clinicians and diabetic decompensation)
* Diagnosis confirmed :
* By the evidence of CPP crystals on synovial fluid examination.
* By the existence of a typical clinical arthritis (joint pain, erythema, swelling, maximal intensity in less than 24h) AND presence of chondrocalcinosis signs in knee, wrists, or pubic symphysis on plain X-rays or crowned tooth in cervical rachis scan.
* Pain VAS ≥ 40/100 at the enrollment
* Duration of symptoms evolution for less than 36h.
* No prior intake of oral steroids, colchicine or NSAIDs for this acute arthritis.
* Signed patient's consent.
* Affiliation to a social security scheme.
Exclusion Criteria:
* Contraindication to colchicine (creatinine clearance below 30ml/min, severe hepatic dysfunction, macrolide or ongoing pristinamycin or macrolid treatment, …) or corticoids utilization (uncontrolled diabetes, uncontrolled progressive infection, uncontrolled arterial hypertension…)
* Severe cognitive disorders that does not allow patient to evaluate his pain.
* Patient under guardianship, curatorship
* Patient receiving morphinic analgesia.
* Gout history or presence of monosodium urate crystals at the examination of the synovial fluid.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
65 Years
Study:
NCT03128905
Study Brief:
Protocol Section:
NCT03128905